Applications published 25 November 2009

Methods for conditional and inducible transgene expression to direct the development of stem cells
The Curators of the University of Missouri 2120544*

Method and device to evaporate active ingredients from a liquid solution
Zobele Holding 2120545*

Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
Roskamp Research 2120557*

Compsns for treating biofilms and methods for using same
Plurogemn Therapeutics 2120561*

Method and compsns for treating HIV infections
Purdue Research Foundation; Mitsuya, Hiroaki; Koh, Yasuhiro 2120562*

• Compounds and uses thereof
AstraZeneca 2120563*

• Benazepine compounds as CGRP receptor antagonists
Merck 2120564*

• Nucleoside cyclic phosphoraidates for the treatment of RNA-dependent RNA viral infection
Merck; Istituto di Ricerche di Biologia Molecolare P Angelettii 2120565*

• Compounds and pharmaceutical compsns for the treatment of viral infections
Idenix Pharmaceuticals; Centre National de la Recherche Scientifique (CNRS) 2120566*

• Prodrugs and substituted 1,3-dioxanes and their uses
Evolva 2120567*

• Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
Celator Pharmaceuticals 2120568*

• Spirochromanon derivatives
Merck; Banyu Pharmaceutical 2120569*

• Treatment of comorbid premature ejaculation and erectile dysfunction
DMI Biosciences 2120570*

• Bifunctional active sites for adsorptionof NOx
The Regents of the University of California 2120571*

• Synthase of unsaturated piperidines from piperidones with a silyl reagent
Janssen Pharmaceutica 2120572*

• Piperidine derivatives
Merck 2120573*

• Sphingosine-1-phosphate receptor agonist and antagonist compounds
Abbott Laboratories 2120575*

• Aminoazoline and urea derivatives for combating animal pests
BASF 2120576*

• Novel solid forms of a microbiocide
Syngenta Ltd; Syngenta Participations 2120577*

• Kinase inhibitor compounds
Xcovery 2120578*

• Inhibitors of poly(ADP-ribose) polymerase
Abbott Laboratories 2120579*

• Compsns and methods for the treatment of metabolic disorders
Baylor College of Medicine 2120580*

• Methods of identifying activators of LYN kinase
Melior Pharmaceuticals 2120581*

• High-dose, long-acting ectoparasiticide for extended control
Wyeth 2120583*

• Silylated piperidine derivatives
Merck 2120584*

• Long-term sustained release pharmaceutical compsn containing aqueous suspension of bisphosphonate
Amphastar Pharmaceuticals 2120585*

• Adjuvants and methods of using them
Archer-Daniels-Midland 2120586*

• Compsns and kits comprising a fungicidal triazole and an alkoxylated alcohol, and their uses
BASF 2120587*

• Use of chroman-4-on-derivatives
Merck Patent 2120855*

• Compsn comprising pyrithione or a polyvalent metal salt of a pyrithione and furametpyr
Procter & Gamble 2120856*

• Effervescent formulations of florfenicol for addition in drinking water systems
Schering-Plough 2120858*

• Sustained-release formulations comprising crystals, macromolecular gels, and particular suspensions of biologic agents
Stryker 2120859*

• Use of a surfactant for the preparation of a formulation for the treatment of adipose diseases
Merz Pharma 2120862*

• Pharmaceutical compsns based on a microemulsion
Nanoderma 2120863*

• A compsn for the administration of biologically active principles in gynaecologic and rectal field and uses thereof
Probiotical 2120864*

• Method of producing a compsn from an oleogl and an aqueous gel and the compsn
Ardana Bioscience 2120865*

• Pharmaceutical compsns for transmucosal delivery of a therpeutically active agent on the basis of submicron particles
PharmaKodex 2120866*

• Low-dose mometasone formulations
Perrigo Israel Pharmaceuticals 2120867*

• Human growth hormone formulations
Altus Pharmaceuticals 2120868*

• Terbinafine formulations for iontophoresis
Power Paper 2120870*

• Linker-based lecithin microemulsion delivery vehicles
Acosta-Zara, Edgar 2120871*

• Nanoemulsion
Biofrontera Bioscience 2120872*